MX9701149A - Particulas similares a retrovirus no infecciosas marcadas de manera antigenica. - Google Patents

Particulas similares a retrovirus no infecciosas marcadas de manera antigenica.

Info

Publication number
MX9701149A
MX9701149A MX9701149A MX9701149A MX9701149A MX 9701149 A MX9701149 A MX 9701149A MX 9701149 A MX9701149 A MX 9701149A MX 9701149 A MX9701149 A MX 9701149A MX 9701149 A MX9701149 A MX 9701149A
Authority
MX
Mexico
Prior art keywords
gene product
particles
marker
retrovirus
infectious
Prior art date
Application number
MX9701149A
Other languages
English (en)
Inventor
Benjamin Rovinski
Shi-Xian Cao
Feilong Yao
Roy Persson
Michel H Klein
Original Assignee
Connaught Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Connaught Lab filed Critical Connaught Lab
Publication of MX9701149A publication Critical patent/MX9701149A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

Las partículas similares a retrovirus no infecciosas comprenden un ensamblaje de un producto de gen env, un producto de gen pol y un producto de ge gag que contiene un marcador antigénico que no es retroviral o retroviral no-HIV. En una modalidad, el marcador comprende una secuencia de aminoácidos que contiene un epítope insertado en el producto de gen gag en un sitio de insercion antigénicamente activo. En otra modalidad, el marcador comprende una secuencia de anclaje antigénico conectada de manera operativa al producto de gen env que reemplaza la funcion de anclaje endogena. En una modalidad adicional, el marcador comprende la modificacion de una region inmunodominante del producto de gen env para evita substancialmente el reconocimiento de la region inmunodominante. Se describen las moléculas deácido nucléico correspondientes, las partículas similares a retrovirus no infecciosas tienen utilidad en la administracion in vivo incluyendo a humanos y en el diagnostico. La presencia del marcador antigénico permite el reconocimiento de que el antisuero que contiene anticuerpos anti-retrovirales se ha generado mediante la exposicion a partículas similares a retrovirus no infecciosas, mediante pruebas para anticuerpos específicos para el marcador antigénico.
MX9701149A 1994-08-15 1995-08-15 Particulas similares a retrovirus no infecciosas marcadas de manera antigenica. MX9701149A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/290,105 US5955342A (en) 1994-08-15 1994-08-15 Non-infectious, replication-defective, self-assembling HIV-1 viral particles containing antigenic markers in the gag coding region
PCT/CA1995/000483 WO1996005292A1 (en) 1994-08-15 1995-08-15 Antigenically-marked non-infectious retrovirus-like particles

Publications (1)

Publication Number Publication Date
MX9701149A true MX9701149A (es) 1997-05-31

Family

ID=23114550

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9701149A MX9701149A (es) 1994-08-15 1995-08-15 Particulas similares a retrovirus no infecciosas marcadas de manera antigenica.

Country Status (12)

Country Link
US (5) US5955342A (es)
EP (1) EP0778888B1 (es)
JP (2) JP3871708B2 (es)
AT (1) ATE331026T1 (es)
AU (1) AU704309B2 (es)
CA (1) CA2197446A1 (es)
DE (1) DE69535075T2 (es)
DK (1) DK0778888T3 (es)
ES (1) ES2268693T3 (es)
MX (1) MX9701149A (es)
PT (1) PT778888E (es)
WO (1) WO1996005292A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080408A (en) * 1994-08-22 2000-06-27 Connaught Laboratories Limited Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
AU702802B2 (en) 1994-10-18 1999-03-04 Scottish Crop Research Institute Method of producing a chimeric protein
WO1996030523A2 (en) * 1995-03-31 1996-10-03 Hans Wolf Antigen presentation system based on retrovirus-like particles
GB9607899D0 (en) * 1996-04-17 1996-06-19 Scottish Crop Research Inst Virus-like particle
US6602505B2 (en) 1998-04-30 2003-08-05 University Of Southern California Viral chimeras comprised of CAEV and HIV-1 genetic elements
CA2331599C (en) 1998-05-12 2005-11-29 Genecure Llc Replication defective hiv vaccine
ES2299276T3 (es) * 1998-12-31 2008-05-16 Novartis Vaccines And Diagnostics, Inc. Polipeptidos env del vih modificados.
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
AU2487300A (en) * 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
WO2000039302A2 (en) 1998-12-31 2000-07-06 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
DE60043708D1 (de) * 1999-10-13 2010-03-04 Novartis Vaccines & Diagnostic Verfahren zur erhaltung zellimmuneantworten gegen proteinen
US8623379B2 (en) * 2000-03-02 2014-01-07 Emory University Compositions and methods for generating an immune response
US20040105871A1 (en) * 2000-03-02 2004-06-03 Robinson Harriet L. Compositions and methods for generating an immune response
CN1311871C (zh) 2000-03-02 2007-04-25 爱莫里大学 Dna表达载体及其应用方法
AU2001270164A1 (en) * 2000-06-26 2002-01-08 The United States Of America As Represented By The Secretary Of Agriculture Production of vaccines using transgenic plants
JP2004522697A (ja) * 2000-09-09 2004-07-29 アクゾ・ノベル・エヌ・ベー Ｅｉａｖキメラワクチンおよび診断
US6461616B1 (en) * 2000-09-09 2002-10-08 Akzo Nobel Nv EIAV p26 deletion vaccine and diagnostic
US7122180B2 (en) * 2000-10-23 2006-10-17 Children's Medical Center Corporation DNA vectors containing mutated HIV proviruses
EP1201750A1 (en) 2000-10-26 2002-05-02 Genopoietic Synthetic viruses and uses thereof
JP4554887B2 (ja) * 2001-03-08 2010-09-29 アメリカ合衆国 改変ＨＩＶエンベロープ、ｇａｇ、およびｐｏｌ遺伝子を発現するＭＶＡ
EP2292772A1 (en) * 2001-07-05 2011-03-09 Novartis Vaccines and Diagnostics, Inc. HIV vaccination with a DNA encoding a HIV polypeptide and a HIV polypeptide
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
CA2458995C (en) * 2001-08-31 2013-04-30 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
US20050106160A1 (en) * 2002-03-05 2005-05-19 Dimitrov Dimiter S. Hiv-1 envelope glycoproteins stabilized by flexible linkers as potent entry inhibitors and immunogens
AU2003278496A1 (en) * 2002-11-14 2004-06-03 Pfizer Products Inc. Use of rmlt as a marker antigen for vaccines and as a synergistic adjuvant with amphigen
EP1989326A4 (en) 2006-01-17 2009-09-30 Health Research Inc BIO-HETERODUPLEX TRACKING TEST
WO2009009215A2 (en) * 2007-05-02 2009-01-15 Emory University Enhancement of glycoprotein incorporation into virus-like particles
EP2550362B1 (en) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352449A (en) * 1986-05-30 1994-10-04 Cambridge Biotech Corporation Vaccine comprising recombinant feline leukemia antigen and saponin adjuvant
GB8923123D0 (en) * 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
JPH05501201A (ja) * 1989-10-16 1993-03-11 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 非感染性ｈｉｖ―１粒子およびそれらの使用
WO1991007425A1 (en) * 1989-11-20 1991-05-30 Oncogen Limited Partnership Non-replicating recombinant-made retroviral particles used as antiviral agents and immunogens
WO1991019803A1 (en) * 1990-06-19 1991-12-26 Applied Biotechnology, Incorporated Self assembled, defective, nonself-propagating viral particles
WO1993020220A1 (en) * 1992-03-27 1993-10-14 Whitehead Institute For Biomedical Research Non-infectious hiv particles and uses therefor
AU4685293A (en) * 1992-07-20 1994-02-14 Immune Response Corporation, The Prophylactic and therapeutic control of retroviral infections
GB9412844D0 (en) * 1994-06-27 1994-08-17 Medical Res Council Improvements in or relating to therapeutic methods

Also Published As

Publication number Publication date
EP0778888A1 (en) 1997-06-18
US5879925A (en) 1999-03-09
CA2197446A1 (en) 1996-02-22
JPH10503933A (ja) 1998-04-14
US5955342A (en) 1999-09-21
PT778888E (pt) 2006-11-30
US6025125A (en) 2000-02-15
ATE331026T1 (de) 2006-07-15
AU704309B2 (en) 1999-04-22
DK0778888T3 (da) 2006-10-23
AU3159995A (en) 1996-03-07
US5866320A (en) 1999-02-02
DE69535075T2 (de) 2007-01-04
JP2006020635A (ja) 2006-01-26
JP3871708B2 (ja) 2007-01-24
WO1996005292A1 (en) 1996-02-22
US5889176A (en) 1999-03-30
ES2268693T3 (es) 2007-03-16
EP0778888B1 (en) 2006-06-21
DE69535075D1 (de) 2006-08-03

Similar Documents

Publication Publication Date Title
MX9701149A (es) Particulas similares a retrovirus no infecciosas marcadas de manera antigenica.
Müller et al. Construction and characterization of a fluorescently labeled infectious human immunodeficiency virus type 1 derivative
AU624628B2 (en) Synthetic vaccine against aids virus
Perrin et al. The influence of the type of immunosorbent on rabies antibody EIA; advantages of purified glycoprotein over whole virus
BR9912177A (pt) Epìtopos de célula auxiliar t artificiais como imunoestimuladores para imunógenos de peptìdeo sintéticos
ES2181717T3 (es) Implante biocompatible para la expresion y la secrecion in vivo de un compuesto terapeutico.
Moore et al. Sensitive ELISA for the gp120 and gp160 surface glycoproteins of HIV-1
DE69535757D1 (de) Rekombinanter immunschwächepoxvirus
CY1114047T1 (el) Νεοι φορεις εκφρασης και χρησεις αυτων
ES554155A0 (es) Un procedimiento para la preparacion de un proteina envolvente de un virus de sindrome de inmunodeficiencia adquirida
ES2099066T3 (es) Antigenos a partir de adn sintetico derivado del virus de la inmunodeficiencia humana (hiv-1).
CA2224003A1 (en) Fluorescence resonance energy transfer screening assay for the identification of hiv-1 envelope glycoprotein-medicated cell
PT1076715E (pt) Células empacotadoras lentivirais
Saah et al. Detection of early antibodies in human immunodeficiency virus infection by enzyme-linked immunosorbent assay, Western blot, and radioimmunoprecipitation
Tang et al. Human immunodeficiency virus type 1 N-terminal capsid mutants containing cores with abnormally high levels of capsid protein and virtually no reverse transcriptase
EP1016671A3 (en) Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of human immunodeficiency virus-1 (HIV-1)
ATE228248T1 (de) Verfahren zur simultanen bestimmung von hiv- antigenen und hiv-antikörpern
Pique et al. The cytoplasmic domain of the human T-cell leukemia virus type I envelope can modulate envelope functions in a cell type-dependent manner
Picard et al. A 2-year follow-up of an anti-HIV immune reaction in HIV-1 gpl60-immunized healthy seronegative humans: Evidence for persistent cell-mediated immunity
EA200300335A1 (ru) Регуляторные и вспомогательные пептиды вич, антигены, вакцинные композиции, набор для иммуноанализа и способ обнаружения антител, индуцируемых вич
Hosmalin et al. Priming with T helper cell epitope peptides enhances the antibody response to the envelope glycoprotein of HIV-1 in primates
ATE198512T1 (de) Transfizierte zelllinien die autoantigene exprimieren und ihre verwendung in immunotests zur erkennung von autoimmunkrankheiten
Spruth et al. Neutralization of HIV type 1 by alloimmune sera derived from polytransfused patients
GB9710154D0 (en) Detection of retroviruses
Mathiesen et al. Acid hydrolysis of serum samples to increase detection of HIV antigen

Legal Events

Date Code Title Description
FG Grant or registration